Ethypharm India, the Indian subsidiary of the French drug delivery pharma major Ethypharm S.A., which announced to out-licensing and supply its Tramadol 50 mg Flashtab to Ranbaxy for the Indian market yesterday, is likely to announce five to six similar marketing and supply deals with various companies within the next five months.
Talking to Pharmabiz, Ajey Kumar, CEO, Ethypharm India said, "The company is in advanced stages of finalising deals with three domestic companies and two overseas companies to market Ethypharm India's products in the field of lifestyle diseases, cardiac care etc. for the national and international markets. The 100 per cent Indian subsidiary, which manufactures 20-30 orals from its parent stable, plus another few products developed by the Indian arm, exports 60 to 70 percent of its production to over 40 countries. The company has strength in pain management, and the new deals would help Ethypharm to maintain the exponential growth in the last few years."
He said the manufacturing facility at Ambernath in an area of 15,000 sq.ft has a capacity to produce 2.3 billion doses of orals. The company is in the process of scaling up the plant with an investment of $ 2 million to meet EUGMP requirements, which will help to scale up production by 20-30% in another 5000 sq.ft area. The R&D facility is also being scaled up with an investment of another $ one million. The expansion would help the company to meet the demand in future, and supplement the requirements of the existing customers.
He said Ethypharm, working with a B2B business model, has already entered into drug supply deals with 12 odd leading companies in India like Ranbaxy, Dabur, NPIL, Elder Pharma etc. The deal with Ranbaxy to supply its Tramadol 50 mg Flashtab is one of the largest drug supply deals in the Indian market, and the company has already started supply as per the agreement.